Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals develops pharmaceutical solutions for diabetes treatment and orally ingestible capsules for polypeptide delivery. Products include oral insulin capsule ORMD-0801, in phase III clinical trials for diabetes and NASH treatment. Other products are in phase II trial for type 2 diabetes treatment. The company also licenses COVID-19 and novel coronavirus vaccines. Incorporated in 2002, headquartered in New York.
Overview
Strengths
- Valued below its Biotechnology peers: P/E 2.4x vs. a median of 20.4x.
- Skin in the game: insiders own 21% of the shares, aligning management with shareholders.
- Cheaper than its own history: P/E 2.4x vs. a historical average of 70.5x.
- Trades below book value (price-to-book 0.76x).
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 9.8% in each of the last 6 years.
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- High leverage: net debt is 3.7x EBITDA, against a median of 0.5x for its Biotechnology peers.
- Unstable profitability: operating margin ranged from -1,502% to -434% over the last 5 years, with operating losses in 5 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 31.7% of total assets.
Key Financial Data